GlassScriptPhysician profile
Michael J Maricic
NPI 1720179971
$109,503.14
in general payments reported to CMS, 2019-2025
19 companies · $86.78 in 2025
The $86.78 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $24K · 2021: $19K · 2022: $25K · 2023: $5,756 · 2024: $584 · 2025: $86.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,188 · Food and Beverage: $1,188 · Education: $50.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,187.50 |
| Food and Beverage | $1,188.31 |
| Education | $50.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $65,335.64 | 2019-2024 | Taltz |
| Amgen INC. | $35,819.41 | 2019-2024 | Evenity, Tavneos, Enbrel |
| Aurinia Pharma U.S., INC. | $3,744.79 | 2022 | |
| Radius Health, INC. | $2,524.47 | 2019-2025 | Tymlos |
| Abbvie INC. | $419.86 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $362.07 | 2021-2024 | Saphnelo |
| Janssen Scientific Affairs, LLC | $205.25 | 2021-2022 | |
| Glaxosmithkline, LLC. | $149.27 | 2019-2022 | |
| Genzyme Corporation | $147.63 | 2019-2024 | |
| Pfizer INC. | $135.51 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $134.04 | 2019 | |
| Genentech USA, INC. | $122.26 | 2019 | |
| Horizon Therapeutics Plc | $111.75 | 2019-2022 | |
| Ucb, INC. | $87.15 | 2019-2024 | Bimzelx |
| Organon LLC | $81.81 | 2023-2025 | Hadlima, Renflexis |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $57.15 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $29.01 | 2019 | |
| Pacira Therapeutics, INC. | $20.95 | 2019 | |
| Orthogenrx INC. | $15.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Maricic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.